ESMO 2021

VGEF antibody plus TKI: the conundrum continues

T-Dxd - a new standard for 2nd line HER2+ MBC

T-Dxd: New treatment paradigm for patients with metastatic HER2+ breast cancer

First study to report OS benefit with CDK4/6i in first line setting for postmenopausal patients

ESMO highlights: Spacing out Ipi; TKI drug holidays, QoL not affected by adjuvant IO

My ESMO melanoma highlights

The game changer: Abiraterone in high risk M0 prostate cancer

Long-term survival with double checkpoint-inhibition

PORT: is the discussion really closed?

Chemoimmunotherapy in 1st line is getting crowded

Pembrolizumab adjuvant in stage II reduces the risk of recurrence, but long-term side effects are possible

DESTINY Breast03: T-Dxd - a new standard for HER2+ MBC

KEYNOTE-355: Pembrolizumab A new option for TNBC

MONALEESA-2: Long Term 1st Line significant overall survival with ribociclib

Ribociclib in 1st line: Long follow-up time confirms OS advantage

New standard of care for HER2+ MBC

T-Dxd: New treatment paradigm for patients with metastatic HER2+ breast cancer

Remarkable improvement of overall survival with ribociclib

Two positive trials reinforce the role of Checkpoint-inhibitors in early and metastatic TNBC

Impressive new data on the improvement of PFS with T-Dxd in patients Her2+ mBC

T-DXd: Impressive results show the potential of ADC technology

T-Dxd - a new standard for 2nd line HER2+ MBC

ESMO21 highlights in metastatic and early breast cancer

Management of Carcinomatous Meningitis (CM) in breast cancer patients

Dose escalation of everolimus in patients with metastatic breast cancer (mBC)

Great results and further research

Survival data confirm pembrolizumab as standard of care

First study to report OS benefit with CDK4/6i in first line setting for postmenopausal patients

Large step forward in HER2+ MBC with T-Dxd

Finally a survival benefit in 1st line metastatic TNBC

A new standard of care for TNBC

Becoming the standard of care for patients with HER2+ MBC

MBC significant data: T-Dxd, Pembrolizumab, Ribciclib

Remarkable survival benefit with Ribociclib defines a new standard of care for patients with HR+ mBC

Ribociclib in 1st line: Lange Nachbeobachtungszeit bestätigt OS-Vorteil

Nareszcie wydłużenie całkowitego czasu przeżycia w 1. linii leczenia zaawansowanego, potrójnie ujemnego raka piersi - KEYNOTE-355

Beneficiu ramarcabil cu Ribociclib in prima linie de tratatment , nou standard la paciente cu cancer mamar metastatic HR+, Her -

Doua trialuri pozitive in tratamentului imunoonologic cu pembrolizumab la pacientele cu cancer mamar timpuriu si metastatic triplu negativ

Dés résultats impressionnants avec les T-DXd en 2ème ligne chez les patientes atteintes d’un cancer HER2-positif métastatique

Risultati straordinari con il T-DXd in seconda linea nelle pazienti con tumore della mammella metastatico HER2 positivo

T-DXd: Beeindruckende Ergebnisse zeigen Potenzial der ADC-Technologie

T-DXd: un nuevo estándar de tratamiento en pacientes con cáncer de mama metastásica HER2 en segunda línea

Punti salienti nel carcinoma mammario metastatico e precoce

Krok milowy w leczeniu zaawansowanego, HER2-dodatniego raka piersi

TNBC: Carboplatinum in neoadjuvant therapy

HER2+: Reduced duration of adjuvant Trastuzumab

TNBC: CPI performing in the neo-adjuvant setting

TNBC Benefit: Pembro + NACT; Carboplatinum

Patient selection allows efficacy and deescalation

Trastuzumab + Lapatinib; reducing the duration of anti-HER2 treatment

High risk patients deserve Pembro

Extended adjuvant Letrozole with significant DFS benefit

Addition of Carbo-Platin with signifcant EFS advantage

Shortening the trastuzumab therapy to 6 months?

Neoadjuvant Giredestrant showed anti-proliverative effect

Carboplatin, a new standard of care in early TNBC?

Verkürzung der Trastuzumab-Therapie auf 6 Monate?

Pembrolizumab - eine Option für high risk Pat.

Aggiunta di carboplatino neoadiuvante con vantaggio significativo in DFS

Estensione del letrozolo adiuvante con vantaggio significativo in DFS

Giredestrant zeigt anti-proliverative Wirkung im neoadjuvanten Setting

Karboplatyna – nowy standard leczenia we wczesnym, potrójnie ujemnym raku piersi?

Patientenselektion mit hoher Wirksamkeit und Deeskalation zugleich

Trastuzumab: Kombination mit Lapatinib und verkürzte HER2- Blockade

BFAST: The Challenge of new biomarkers for immunotherapy

Upcoming therapy options in oncogenic-driven NSCLC

IO combinations in advanced NSCLC - revolution and challenges at the same time

New options for 2nd line after IO-failure

Are vaccines the way forward after progressing on immunotherapy?

KRASG12C and platinum doublet chemotherapy: does the backbone matter?

New options in salvage setting for EGFR-mutant patients

New opportunitiy to treat HER2-mutated lung cancer

Poziotinib in HER2 mutated lung cancer

EGFR TKI plus VEGF inhibition

Potential new biomarker for immunotherapy

2nd line option after IO failure

New 1st line option

VGEF antibody plus TKI: the conundrum continues

New ADC for lung cancer

Cemiplimab + chemotherapy: 1st presentation of EMPOWER-Lung3 data

Gavo-cel dose escalation in refractory mesothelin-expressing solid tumors

HER2 mutations: new opportunities effective

Chemoimmunotherapy in 1st line is getting crowded

Trastuzumab Deruxtecan, a new option for HER2+ lung cancer

Failure to demonstrate PFS-improvement when combining bevacicumab and osimertinib

A new treatment for HER2-mutated NSCLC

Nuevas terapias en linea avanzada de pacientes con mutaciones de EGFR

Un nouveau traitement pour le CBNPC HER2-muté

Nuevas opciones terapéuticas en segunda linea tras fallo a inmunoterapia

Kein Vorteil für Anti-IL1 AK

CAR-T-Zell-Therapie auch bei refraktären Karzinompatienten?

Neues AWK beim Lungenkarzinom

Cemilimab + Chemotherapie: Erste Daten der EMPOWER-Lung3

HER2 Mutation: Drug-Immuno-Conjugates effektiv

Chemoimmuntherapie 1st line: Wohin führt POSEIDON?

le TdxD, nouvelle option pour les CBNPC HER2+?

Absence d'amélioration de la SSP en associant le bevacicumab et l'osimertinib

Stage III NSCLC - the new stage IV ?!

Immune checkpoint inhibitors - on the way to standard therapy in early stage NSCLC

PORT: is the discussion really closed?

Update on chemoradiation for stage III NSCLC

Wind of change?

New option in unresectable NSCLC?

Endpoint pathological response in induction therapy with immun checkpoint inhibition

Update on IMpower010

COAST on the horizon

Completing the picture

IO mono-Induction: window of opportunity to guide immunotherapy

Durvalumab consolidation in a real world setting

Immunotherapy improves PFS after sequential or concomittant radiochemotherapy

Potential new standard of care in NSCLC

The power of randomization

Inflection point in next generation drug development

The benefit of adjuvant atezolizumab in PD-L1 low

Zijn vaccins de toekomst na progressie op immunotherapie?

Postoperatie radiotherapie bij N2 ziekte: is de discussie nu echt gesloten?

KRASG12C en platinum doublet chemotherapie: maakt de combinatie wat uit?

IMpower010 Update: Stellenwert von Atezolizumab bestätigt

Neue IO-Kombinationen vielversprechend

nouve opzioni per lo NSCLC Stadio III inoperabile?

Pathological Response als Endpunkt bei Induktionstherapie mit immuncheckpoint-Inhibition

Update IMpower010

Neue Horizonte durch COAST

Learnings from IMpower010

IO Mono Induktion - Zeitfenster für Immuntherapie

Quelle efficacité du durvalumab en pratique clinique?

L'immunothérapie améliore la SSP après une radiochimiothérapie séquentielle ou concomitante

Update on important phase III trials

The tail matters even in ES-SCLC

Actualizaciones en estudios fase III

la coda conta anche nel SCLC in malattia estesa

NIVOTHYM: Immunotherapy for thymic tumors

Is there a role for immunotherapy for thymic tumors?

Quelle place de l’immunothérapie pour les tumeurs thymiques? Essai NIVOTHYM

New era in mesothelioma – stay tuned!

Update on important phase III trials

IO-IO, the way to go in mesothelioma

IO-IO, la strada da percorrere nel mesotelioma

Actualizaciones en estudios fase III

Langzeitüberleben durch IO

RELATIVITY-047: Subgroup updates; Enduring benefit and prolonged PFS2

CheckMate 204: Brain metastases - Promising achievements

New data for BRAF-mutated melanoma patients

KEYNOTE-716: Adjuvant pembrolizumab in stage IIB/C

MASTERKEY-265: Pembrolizumab +/- T-VEC

My ESMO melanoma highlights

Highlights from this year's ESMO

Additional efficacy and shifts in treatment options

New strategies for adjuvant stage II

Pembrolizumab is a good option for adjuvant stage IIB/C

LAG-3-blocking ab shows benefit in combination with Nivo

Nivo/Ipi for brain metastatses

No preference for sequential therapy

A 5 year update

No significant improvement

Promising data, but some questions remain

Pembrolizumab adjuvant in stage II reduces the risk of recurrence, but long-term side effects are possible

T-VEC is not a convincing partner for CPI

5 year update

First data using immunotherapy as an adjuvant mechanism in stage II

Sequencing - start with immunotherapy first

Personalized treatment for patients according to IFN-γ sign

ESMO 2021: updates on the SECOMBIT study

T-VEC überzeugt nicht als Partner für CPI

5 Jahres Update

ESMO 2021: aggiornamenti dello studio SECOMBIT

Pembro gute Option adjuvant im Stad. IIB/C

LAG-3-AK zeigt Benefit in Kombi mit Nivo

Nivo-Ipi bei Hirnmetastasen

Keine Präferenz bei sequenzieller Therapie

Pembro adj. im Stad. II verringert Rezidivrisiko, aber Langzeit-NW möglich

PRO results support adjuvant IO efficacy, some questions still open!

Maintaining the IO-combination with higher flexibility.

ESMO highlights: Spacing out Ipi; TKI drug holidays, QoL not affected by adjuvant IO

Update adjuvant immunotherapy

Dual immunotherapy update

Quality of Life in adjuvant immunotherapy

HIF-2α- a promising target?

Long-term survival with double checkpoint-inhibition

Role of cytoreductive nephrectomy in patients treated with TKI/IO combination

Increased flexibility for side effects due to ipilimumab

Spannende Daten, wenn auch nicht "game-changing"

Ipi mit festem Stellenwert beim aRCC

Höhere Flexibilität bei Nebenwirkungen durch Ipilimumab

HIF-2α - una diana prometedora?

VESPER: Do we have to intensify perioperative chemotherapy in bladder cancer?

NABUCCO: IPI matters – discussion on benefits in bladder cancer

VESPER neoadjuvant chemotherapy phase 3 trial in MIBC

ESMO21:The highlights of Bladder cancer

ESMO highlights: new combinations FGFRa, Pembro+sEphB4, ddMVAC ...

ipilimumab-nivolumab opportunities for alternative regimens

Strong signal regarding PFS and OS in ddMVAC

Improving patients outcome in bladder cancer

Deciphering strategies for immunotherapy combinations

PD-L1 as predictor of survival in DANUBE phase III trial in metastatic urothelial carcinoma

Novita’ in tema di tumori vescicali dal congresso ESMO 2021

Ipilimumab-Nivolumab Möglichkeiten für alternative Regime

Starkes Signal bezüglich PFS und OS bei ddMVAC

Mejorando el futuro de los pacientes con cáncer de vejiga.

Descifrando las estrategias para mejorar las combinaciones con inmunoterapia

PDL-1 como predictor de supervivencia en cáncer de vejiga metastásico. Analizando el estudio fase III DANUBE

STAMPEDE: Practice changing in high-risk non-metastatic M0 Pca

ARCHES & PEACE-1: From doublets to triplets in mHSPC?

COSMIC-021: mCRPC perspectives in later Lines.

Hope for patients with mCRPC

The game changer: Abiraterone in high risk M0 prostate cancer

Is it really practice changing?

Significant advances in M0 PCa

DS7300 - an exciting novel therapy in prostate cancer and beyond

More data for extending Enzalutamide's label for mHSPC

Chemo Upront: Consider combination with Abiraterone

Practice changing results for mHSCP

New data change our practice in non-metastatic high-risk PC

Survival benefit with triplet therapy for mHSPC

Enzalutamide added to ADT shows clear survival benefit with longer follow-up in the ARCHES study

Combination therapies and new targeted therapies in advanced prostate cancer

New promising Combination with Pembro and lu-PSMA

Triplet or duplet for high-risk patients

PSMA – RLT is here!

Is triplet therapy the new SOC?

DD-MVAC is the new SOC!

STAMPEDE trial: new standard of care for localized high risk prostate cancer (ADT/RT/ABI)

PEACE-1 phase 3 trial in metastatic CSPC

mHSPC: ADT alone is not enough!

Hoffnung für Patienten mit mCRPC

Resultat från STAMPEDE öppnar för ny kombinationsbehandling vid icke metastaserad hormonkänslig prostatacancer

PEACE-1 studien visar överlevnadsvinst med trippel behandling vid metastaserad hormonkänslig prostatacancer

Längre uppföljningstid I ARCHES-studien visar klar överlevnadsvinst med enzalutamid som tillägg till kastrationsbehandling vi nydiagnostiserad metastaserad hormonkänslig prostatacancer

Kombinationsbehandlingar och nya riktade terapier vid avancerad prostatacancer

Neue vielversprechende Kombination mit Pembro und lu-PSMA

Triplet oder Duplette beim hochrisiko Patienten

Μεταστατικός ορμόνο ευαίσθητος καρκίνος προστάτη: Η θεραπεία με lhrh ανάλογα μόνο δεν είναι αρκετή

Σημαντικό όφελος με την προσθήκη άμπιρατερονης Στην θεραπεία ασθενών με υψηλού ρίσκου τοπικό περιοχικο Καρκίνο προστάτη

Ein weiteres Puzzlestück für Zulassungserweiterung von Enzalutamide beim mHSPC

Chemo Upfront: Kombination mit Abiraterone bedenken!

CAR-T-Zell-Therapie auch bei refraktären Karzinompatienten?

Covid19 & Cancer: updates from ESMO 2021